We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC WRAPS UP BIOVAIL TEVETEN PATENT INQUIRY
FTC WRAPS UP BIOVAIL TEVETEN PATENT INQUIRY
January 2, 2004
The FTC will take no action against Biovail, closing its inquiry into the firm’s Orange Book patent listings for the blood pressure products Teveten and Teveten HCT, Biovail announced Dec. 22.